Cytokinetics, Incorporated (NASDAQ:CYTK) Receives $71.58 Consensus Price Target from Brokerages
Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the fifteen analysts that are currently covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation, ten have assigned a buy recommendation and two have given a strong buy recommendation to […]
More Stories
Subaru Recalls Nearly 70,000 Vehicles for Fuel Leak Risk, Issues ‘Park Outside’ Warning
By Mary Prenon Subaru and Kia America have both issued recalls involving thousands of vehicles with elevated risks for accidents...
Melania Trump Set to Make History by Chairing UN Security Council Meeting
By Evgenia Filimianova U.S. First Lady Melania Trump will make history on March 2 when she presides over a U.N....
British Prime Minister Suffers Major By-Election Defeat as Epstein Scandal Casts Pall
By Chris Summers The ruling Labour Party in the UK was beaten into third place on Feb. 26 in a...
US Producer Inflation Rises More Than Expected in January
By Andrew Moran A key pipeline inflation indicator unexpectedly increased in January, potentially signaling higher consumer prices in the coming...
Recurring Unemployment Claims Decline to 1-Month Low
By Andrew Moran In a potential signal that the U.S. labor market could be on the cusp of renewed hiring...
US Treasury to Allow Resale of Venezuelan Oil to Cuba to Ease Island’s Fuel Crunch
By Kimberly Hayek The U.S. Treasury Department on Wednesday announced a new licensing policy to streamline the resale of Venezuelan...